**Core Concept**
Ranolazine is a medication that affects the late sodium current (INa) in cardiac myocytes, leading to a reduction in intracellular sodium levels. This action has a beneficial effect on myocardial ischemia, particularly in patients with angina pectoris.

**Why the Correct Answer is Right**
Ranolazine works by selectively inhibiting the late sodium current (INa) in cardiac myocytes, which reduces the influx of sodium ions into the cell. This reduction in intracellular sodium levels decreases the amount of calcium ions released from the sarcoplasmic reticulum, thereby reducing intracellular calcium overload. As a result, ranolazine decreases the energy demand of the heart and improves myocardial ischemia. This unique mechanism of action is distinct from other anti-anginal medications, such as beta-blockers and calcium channel blockers.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because ranolazine is not a beta-blocker, which works by reducing heart rate and contractility.
**Option B:** Incorrect because ranolazine is not a calcium channel blocker, which works by reducing calcium influx into cardiac myocytes.
**Option C:** Incorrect because ranolazine is not a potassium channel opener, which works by increasing potassium efflux from cardiac myocytes.

**Clinical Pearl / High-Yield Fact**
Ranolazine is a useful alternative for patients with angina who are intolerant to beta-blockers or calcium channel blockers, as it has a distinct mechanism of action and a favorable side effect profile.

**Correct Answer:** C. Antianginal agent.